




RealRate

PHARMACEUTICAL 2021

Heron Therapeutics INC DE
Rank 226 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Heron Therapeutics INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Heron Therapeutics INC DE compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Heron Therapeutics INC DE is the variable Expenses, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 8.7% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	314,196
Cost of Goods Sold	36,189
Intangible Assets	0
Liabilities, Current	102,503
Liabilities, Non-Current	14,561
Other Assets	16,623
Other Compr. Net Income	172
Other Expenses	63,853
Other Liabilities	0
Other Net Income	885
Other Revenues	88,638
Property and Equipment	22,737
Research and Development	174,533
Selling, General and Administrative Expense	42,226

Output Variable	Value in 1000 USD
Assets	353,556
Liabilities	117,064
Expenses	316,801
Revenues	88,638
Stockholders Equity	236,492
Net Income	-227,278
Comprehensive Net Income	-227,192
BaseVar	438,558
ECR before Limited Liability	123%
Economic Capital Ratio	248%